Cellular LanthaScreen and β-lactamase reporter assays for high-throughput screening of JAK2 inhibitors

Assay and Drug Development Technologies

Volumn 6, Issue 4, 2008, Pages 519-529

  Robers, Matthew B ^a   Machleidt, Thomas ^a   Carlson, Coby B ^a   Bi, Kun ^a  

^a INVITROGEN CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAMASE; ERYTHROPOIETIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GREEN FLUORESCENT PROTEIN; HYBRID PROTEIN; INTERLEUKIN 3; JANUS KINASE 2; JANUS KINASE INHIBITOR; STAT5 PROTEIN;

ARTICLE; DIMERIZATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME ASSAY; ENZYME PHOSPHORYLATION; ERYTHROLEUKEMIA CELL; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; RNA INTERFERENCE; TRANSACTIVATION;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CELL PROLIFERATION; CELLS, CULTURED; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENES, REPORTER; GENETIC VECTORS; HUMANS; INDICATORS AND REAGENTS; JANUS KINASE 2; MICROSCOPY, FLUORESCENCE; REPRODUCIBILITY OF RESULTS; RNA, SMALL INTERFERING;

EID: 51849083849     PISSN: 1540658X     EISSN: None     Source Type: Journal    
DOI: 10.1089/adt.2008.144     Document Type: Article

References (16)

1. O'Shea JJ, Pesu M, Borie DC, Changelian PS: A new modality for immunosuppression: targeting the JAK/STAT pathway. Nat Rev Drug Discov 2004;3:555-564.
2. Ferrajoli A, Faderl S, Ravandi F, Estrov Z: The JAK-STAT pathway: a therapeutic target in hematological malignancies. Curr Cancer Drug Targets 2006;6:671-679.
3. Schindler C, Levy DE, Decker T: JAK-STAT signaling: from interferons to cytokines. J Biol Chem 2007;282:20059-20063.
4. Ihle JN, Gilliland DG: Jak2: normal function and role in hematopoietic disorders. Curr Opin Genet Dev 2007;17:8-14.
5. Lacronique V, Boureux A, Valle VD, Poirel H, Quang CT, Mauchauffe M, et al.: A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 1997;278:1309-1312.
6. James C, Ugo V, Casadevall N, Constantinescu SN, Vainchenker W: A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects. Trends Mol Med 2005;11:546-554.
7. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al.: Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-1061.
8. Zlokarnik G, Negulescu PA, Knapp TE, Mere L, Burres N, Feng L, et al.: Quantitation of transcription and clonal selection of single living cells with beta-lactamase as reporter. Science 1998;279:84-88.
9. Robers MB, Horton RA, Bercher MR, Vogel KW, Machleidt T: High-throughput cellular assays for regulated posttranslational modifications. Anal Biochem 2008;372:189-197.
10. Kitamura T, Tange T, Terasawa T, Chiba S, Kuwaki T, Miyagawa K, et al.: Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin. J Cell Physiol 1989;140:323-334.
11. Riddle SM, Vedvik KL, Hanson GT, Vogel KW: Time-resolved fluorescence resonance energy transfer kinase assays using physiological protein substrates: applications of terbium-fluorescein and terbium-green fluorescent protein fluorescence resonance energy transfer pairs. Anal Biochem 2006;356:108-116.
12. Liu RY, Fan C, Garcia R, Jove R, Zuckerman KS: Constitutive activation of the JAK2/STAT5 signal transduction pathway correlates with growth factor independence of megakaryocytic leukemic cell lines. Blood 1999;93:2369-2379.
13. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et al.: Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-397.
14. Vogel K, Zhong Z, Bi K, Pollok B: Developing assays for drug discovery - where have the advances come from. Expert Opin Drug Discov 2008;3:115-125.
15. Binder C, Lafayette A, Archibeque I, Sun Y, Plewa C, Sinclair A, et al.: Optimization and utilization of the SureFire phospho-STAT5 assay for a cell-based screening campaign. Assay Drug Dev Technol 2008;6:27-37.
16. Peekhaus NT, Ferrer M, Chang T, Kornienko O, Schneeweis JE, Smith TS, et al.: A β-lactamase-dependent Gal4-estrogen receptor β transactivation assay for the ultra-high throughput screening of estrogen receptor β agonists in a 3456-well format. Assay Drug Dev Technol 2003;1:789-800.